Review anchor
Transient receptor potential cation channel subfamily V member 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Transient receptor potential cation channel subfamily V member 1
CHEMBL4794
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Transient receptor potential cation channel subfamily V member 1 as ChEMBL target CHEMBL4794, mapped to UniProt Q8NER1. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4794
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8NER1
Transient receptor potential cation channel subfamily V member 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Transient receptor potential cation channel subfamily V member 1 matters
Transient receptor potential cation channel subfamily V member 1 is reviewed as Transient receptor potential cation channel subfamily V member 1 (UniProt Q8NER1); Transient receptor potential cation channel subfamily V member 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 5675 compounds, and 649 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Transient receptor potential cation channel subfamily V member 1
Transient receptor potential cation channel subfamily V member 1 Sequence length is 839 aa.
Review this target as Transient receptor potential cation channel subfamily V member 1, mapped to UniProt Q8NER1. Sequence length is 839 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q8NER1
Protein
Disease context
pain
Transient receptor potential cation channel subfamily V member 1 shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACETAMINOPHEN, AZD1386, CAPSAICIN.
Start review with pain because it currently carries approved-linked support. Linked drugs include ACETAMINOPHEN, AZD1386, CAPSAICIN, NGD-8243. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
6 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 6 approved drugs, 5675 compounds, and 649 assays for this target. The dominant activity type is IC50. CHEMBL2177429 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL2177429 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
6 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Transient receptor potential cation channel subfamily V member 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8NER1, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why pain is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5675
Total Compounds
649
Total Assays
6
Approved Drugs
IC50: 4628.0, KI: 1178.0, EC50: 675.0, KD: 11.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2177429
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL17976
|
10.7 | EC50 | Clinical |
|
|
No preferred name
CHEMBL3407762
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL2177428
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL3393837
|
10.7 | Ki | — |
Approved Drugs
Source Header